The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy

The prognostic value of systemic immune-inflammation index in patients with unresectable hepatocellular carcinoma treated with immune-based therapy

Abstract Background Predicting the efficacy of immune-based therapy in patients with unresectable hepatocellular carcinoma (HCC) remains a clinical challenge. This study aims to evaluate the prognostic value of the systemic immune-inflammation index (SII) in forecasting treatment response and surviv...

Full description

Saved in:

Bibliographic Details
Main Authors:	Tian He, Bin Xu, Lu-Na Wang, Zi-Yi Wang, Huan-Chen Shi, Cheng-Jie Zhong, Xiao-Dong Zhu, Ying-Hao Shen, Jian Zhou, Jia Fan, Hui-Chuan Sun, Bo Hu, Cheng Huang
Format:	Article
Language:	English
Published:	BMC 2025-01-01
Series:	Biomarker Research
Subjects:	Hepatocellular carcinoma Immune-based therapy Atezolizumab-bevacizumab Systemic immune-inflammation index (SII) Prognosis
Online Access:	https://doi.org/10.1186/s40364-024-00722-6
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan
by: Jaekyung Cheon, et al.
Published: (2025-01-01)

Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma
by: Parissa Tabrizian, et al.
Published: (2025-02-01)

Effect of Proteinuria Before Lenvatinib Administration on Treatment Response After Atezolizumab Bevacizumab Combination Therapy
by: Hironori Ochi, et al.
Published: (2025-01-01)

Second-line treatment patterns and outcomes in advanced HCC after progression on atezolizumab/bevacizumab
by: Meng Wu, et al.
Published: (2025-02-01)

Three effective cases of transcatheter arterial embolization after atezolizumab and bevacizumab treatment for hepatocellular carcinoma: a case report
by: Koji Rinka, et al.
Published: (2025-01-01)

Prognostic value of systemic immune-inflammation index for patients undergoing radical prostatectomy: a systematic review and meta-analysis
by: Zhan Chen, et al.
Published: (2025-02-01)

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis
by: Jie Dai, et al.
Published: (2025-01-01)

Habitat radiomics based on CT images to predict survival and immune status in hepatocellular carcinoma, a multi-cohort validation study
by: Kun Chen, et al.
Published: (2025-02-01)

New inflammatory markers associated with disease activity in rheumatoid arthritis: pan-immune-inflammation value, systemic immune-inflammation index, and systemic inflammation response index
by: İpek Okutan, et al.
Published: (2024-12-01)

Therapeutic efficacy and prognostic indicators in re-resection for recurrent hepatocellular carcinoma: Insights from a retrospective study
by: Qi Fan, MM, et al.
Published: (2025-01-01)

Harnessing nanoparticles for reshaping tumor immune microenvironment of hepatocellular carcinoma
by: JinSong Li, et al.
Published: (2025-02-01)

The Clinical Value of the Combined Detection of Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and Prognostic Nutritional Index (PNI) in Early Diagnosis of Gastric Cancer
by: Zheng J, et al.
Published: (2025-01-01)

Mutual causal effects between immune cells and hepatocellular carcinoma: a Mendelian randomization study
by: Zheng Wang, et al.
Published: (2025-01-01)

Prognostic impact of presenting symptoms of patients with hepatocellular carcinoma
by: Samuel Jun Ming Lim, et al.
Published: (2024-08-01)

Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma
by: Atsushi Naganuma, et al.
Published: (2025-01-01)

Genetic Determinants of Immune Cells and Hepatocellular Carcinoma Risk: A Bioinformatics and Bidirectional Mendelian Randomization Study
by: Tong WU, et al.
Published: (2025-01-01)

NOL-7 serves as a potential prognostic-related biomarker for hepatocellular carcinoma
by: Qiucheng Lei, et al.
Published: (2025-01-01)

Heterogeneity in polyamine metabolism dictates prognosis and immune checkpoint blockade response in hepatocellular carcinoma
by: Jianyan Pan, et al.
Published: (2025-02-01)

The expression landscape and clinical significance of methyltransferase-like 17 in human cancer and hepatocellular carcinoma: a pan-cancer analysis using multiple databases
by: Yezhou Ding, et al.
Published: (2025-01-01)

Prognostic value and clinicopathological significance of pre-and post-treatment systemic immune-inflammation index in colorectal cancer patients: a meta-analysis
by: Yueting Tan, et al.
Published: (2025-01-01)

Liver Transplantation in the Treatment of Unresectable Hepatocellular Carcinoma in the Absence of Liver Cirrhosis
by: O. D. Olisov, et al.
Published: (2018-09-01)

A new signature associated with anoikis predicts the outcome and immune infiltration in nasopharyngeal carcinoma
by: Yonglin Luo, et al.
Published: (2025-02-01)

The prognostic importance of the pan-immune-inflammation value in patients with septic shock
by: Yasemin Bozkurt Turan
Published: (2024-01-01)

Identification of Hepatocellular Carcinoma Subtypes Based on Global Gene Expression Profiling to Predict the Prognosis and Potential Therapeutic Drugs
by: Cunzhen Zhang, et al.
Published: (2025-01-01)

Immune infiltration landscape and potential drug-targeted implications for hepatocellular carcinoma with ‘progression/hyper-progression’ recurrence
by: Jing-Xuan Xu, et al.
Published: (2025-12-01)

Prognostic and diagnostic significance of circRNAs expression in hepatocellular carcinoma patients: A meta‐analysis
by: Xin Huang, et al.
Published: (2019-03-01)

Identification and validation of prognostic biomarkers in ccRCC: immune-stromal score and survival prediction
by: Fang Lyu, et al.
Published: (2025-01-01)

Adropin: a key player in immune cell homeostasis and regulation of inflammation in several diseases
by: Junmin Wang, et al.
Published: (2025-01-01)

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis
by: Shang‐Gin Wu, et al.
Published: (2025-01-01)

RETRACTED ARTICLE: Construction and validation of a machine learning-based immune-related prognostic model for glioma
by: Qi Mao, et al.
Published: (2024-10-01)

TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
by: Wang W, et al.
Published: (2025-01-01)

Systemic Immune-inflammation Index in Evaluation of Inflammation in Rheumatoid Arthritis Patients
by: Amela DERVISEVIC, et al.
Published: (2024-09-01)

Trajectories of systemic immune inflammation index and mortality risk in patients with moderate-to-severe traumatic brain injury: a retrospective cohort study
by: Zhiyong Tang, et al.
Published: (2025-02-01)

Association between the systemic immune-inflammation index and sarcopenia in older adults: a cross-sectional study
by: Esra Cataltepe, et al.
Published: (2025-01-01)

Reversing NK cell exhaustion: a novel strategy combining immune checkpoint blockade with drug sensitivity enhancement in the treatment of hepatocellular carcinoma
by: Yuxiang Huang, et al.
Published: (2025-01-01)

The XIAP inhibitor AZD5582 improves the treatment effect of microwave ablation on hepatocellular carcinoma
by: Wenhui Wang, et al.
Published: (2025-01-01)

HLA-DMB correlates with antitumor immunity and an improved prognosis in endometrial carcinoma tumors
by: Xiaoyu Xi, et al.
Published: (2025-01-01)

NIPAL1 as a prognostic biomarker associated with pancreatic adenocarcinoma progression and immune infiltration
by: Youlong Zhu, et al.
Published: (2025-01-01)

Tolerability and Effectiveness of Regorafenib Treatment in Patients with Unresectable Hepatocellular Carcinoma: Real-World Data from the United States
by: Finn RS, et al.
Published: (2025-02-01)

Clinical Implications of Pan-Immune-inflammatory Values in Patients with Hypertrophic Cardiomyopathy
by: Levent PAY, et al.
Published: (2024-12-01)